Advances in Treatment of Myasthenia Gravis

This neurological update details the substantial advancements in treating Myasthenia Gravis (MG), emphasizing transformative developments since 2016. A major focus is the proven efficacy of thymectomy in non-thymomatous disease and the introduction of novel targeted immunotherapies, including complement inhibitors and FcRN inhibitors that actively remove pathogenic antibodies from circulation. Current clinical guidelines are evolving to incorporate these medications for early and aggressive management, acknowledging differing mechanisms and therapeutic responses between AChR-antibody positive and MuSK-antibody positive patient cohorts. The review also examines the impact of demographics, noting the rising incidence of Late-Onset MG (LOMG) and the necessity of tailoring treatment regimens for the aging population. Finally, the authors express optimism regarding future prospects, citing the need for better biomarkers to enable precision medicine and the development of curative approaches like CAR T cell therapy.